Advertisement

ADVERTISEMENT

FDA

News
FDA Approves First Treatment for Episodic Cluster Headaches
06/05/2019
After a clinical trial showed the treatment was more effective than placebo, the FDA approved the first treatment for episodic cluster headache in adults that reduces the frequency of attacks.
After a clinical trial showed the treatment was more effective than placebo, the FDA approved the first treatment for episodic cluster headache in adults that reduces the frequency of attacks.
After a clinical trial showed...
06/05/2019
Neurology
News
FDA Approves Another New MS Treatment
04/01/2019
Following a clinical trial testing its safety and efficacy, the FDA has approved a new oral treatment for patients with relapsing forms of multiple sclerosis.
Following a clinical trial testing its safety and efficacy, the FDA has approved a new oral treatment for patients with relapsing forms of multiple sclerosis.
Following a clinical trial...
04/01/2019
Neurology
News
FDA Approves New Drug for Chronic Idiopathic Constipation
12/20/2018
The FDA has approved a selective serotonin-4 (5-HT4) receptor agonist to treat adults with chronic idiopathic constipation, a condition that affects 14% of the adult population.
The FDA has approved a selective serotonin-4 (5-HT4) receptor agonist to treat adults with chronic idiopathic constipation, a condition that affects 14% of the adult population.
The FDA has approved a selective...
12/20/2018
Gastroenterology
News
FDA Approves First Treatment for Rare Nerve Disease
08/10/2018
The US Food and Drug Administration has granted approval to the first treatment in a new drug class for a nerve condition that affects about 50,000 people worldwide.
The US Food and Drug Administration has granted approval to the first treatment in a new drug class for a nerve condition that affects about 50,000 people worldwide.
The US Food and Drug...
08/10/2018
Neurology
News
FDA Advisory on Concomitant Migraine, Depression Meds Questioned
02/27/2018
In 2006, the US Food and Drug Administration issued an advisory that warned of the risk for serotonin syndrome with concomitant use of triptans and certain antidepressants. In a recent study, researchers aimed to assess this risk further.
In 2006, the US Food and Drug Administration issued an advisory that warned of the risk for serotonin syndrome with concomitant use of triptans and certain antidepressants. In a recent study, researchers aimed to assess this risk further.
In 2006, the US Food and Drug...
02/27/2018
Neurology
News
FDA: First Blood Test for Concussion Diagnosis Approved
02/15/2018
The US Food and Drug Administration recently approved the first blood test to aid in assessing mild traumatic brain injury in adults.
The US Food and Drug Administration recently approved the first blood test to aid in assessing mild traumatic brain injury in adults.
The US Food and Drug...
02/15/2018
Neurology
Research in Review
FDA Hematology-Oncology Reviewers Move on to Consult or Work for Biopharmaceutical Companies
09/30/2016
JCP Editors
Medical reviewers at the US Food and Drug Administration are an important part of regulating therapeutics and ensuring that patients have access to the right medications, but a recent letter published in BMJ has...
Medical reviewers at the US Food and Drug Administration are an important part of regulating therapeutics and ensuring that patients have access to the right medications, but a recent letter published in BMJ has...
...
09/30/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use